《生命科学――一场全球性变革》

G. 史蒂文著，博乐生命科学传媒集团有限公司，2007年3月英文版（暂无中文版）。

Burrill Biotechnology Serious Report from 2007-2009

Burrill is the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publishes a wide range of bio-intelligence reports including: its annual State of the Industry, The Personalized Medicine Report, The Stem Cell Report, and periodic newsletters covering Canada, China, Europe, India, Japan and Partnering/M&A. Burrill also publishes The Burrill Report,  a bimonthly magazine.

Biotech 2009 - Life Sciences: Navigating the Sea Change (Print)

Sea change: Noun: a striking change, as in appearance, often for the better

Biotech 2009-Life Sciences: Navigating the Sea Change is the 23^rd edition of this yearly publication. It provides a compass to guide you through the current financial market turmoil. The 400-plus page book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond.

The biotech industry has had nearly 40 years of easy access to inexpensive capital. The capital markets have permanently restructured, making access to capital more difficult and expensive to access. The changes mean:

§         Buy-side interest and resources are reduced.

§         Venture capitalist and private investors no longer can rely on IPOs for exits.

§         Big Pharma is not as eager to make deals. As these companies see it, technology will be cheaper to buy if they wait.

§         Falling oil prices may slow the momentum for alternate fuels.

These issues will be discussed in depth in the following chapters:

1. Navigating the sea change: An overview of the challenges ahead.
2. Industry Metrics: Burrill & Company's critical statistics on the life sciences, presented in a clear and easy-to-use format. 
3. Healthcare: The cost of health, trends in healthcare delivery, ideas for reform including electronic health records and personal health records, large cap biotech and pharma industry models and metrics
4. Personalizing Medicine: Systems biology, biomarkers and diagnostics, personalized medicine, targeted therapies, genomics, and combination devices.
5. Wellness: Healthful foods and eating; prevention of sickness; corporate takeover of prevention (wellness tied to healthcare), uptake of personal genomics and social networking for wellness.
6. Emerging Technologies: Stem cells and regenerative medicine, nanomedicine, RNAi, whole genome scanning and implantable sensors
7. Politics and Policy: Healthcare, U.S. Food and Drug Adminstration, and Centers for Medicare & Medicaid Services, what the new administration portends, patent reform.
8. Agbio/Biofuels/Industrial Biotech/Cleantech: Next generation biofuels, feedstocks, enzymes and crops. 
9. International: Profiles and initiatives of the expanding life sciences industry in Canada, Europe, China, India, Malaysia, Latin America, Middle East. 
10. M&A/Partnering: Dealmaking around the globe. 
11. Finance and Capital Markets: Performance of biotechnology companies on the capital markets and analysis of 2008 fundraising. 

The publication also includes a detailed analysis and charts on:

-          Total Global Industry Financings

o        By Public Companies

o        By Private Companies

o        By Therapeutic Class

      -     Industry Market Cap

-          Global Industry Financials

o        Revenues

o        Research and Development

o        Profit (Loss)

o        Cash and Cash Equivalents

-          2008 Partnering deals

-          2008 Mergers & Acquisitions

PLEASE NOTE: THIS IS A SPECIAL PRE-PUBLICATION PRICE. THIS BOOK IS EXPECTED TO SHIP MARCH 7, 2009.

Biotech 2008: A 20/20 Vision To 2020 (Print)

Download the executive summary and TOC

The publication includes:

·                                 Biotech in 2020

·                                 2007 Industry Financials, including 12 months of company financial data and market caps for the US, Europe, Canada, and Asia

·                                 Analysis of key activities across industry sectors including healthcare, personalized, predictive and, preventive medicine, wellness, ag-biotech, industrial biotechnology and biofuels

·                                 Highlights of the most important recent advances in technology including stem cells and nanotechnology

·                                 Politics and Policy - with special features on the presidential campaign and how it is likely to affect the life sciences industry

·                                 Analysis of deal making, the venture capital environment and capital markets

·                                 The biotech industry around the world - Canada, Europe, Asia, with special features on emerging global players such as China, India, Malaysia, Brazil

BIOTECH 2007 (Print)

BIOTECH 2007 (Print) The 21st Edition of BIOTECH 2007 focuses on the emergence of biotechnology as a global industry. This publication provides an overview of the latest developments and trends in biotech around the world along with detailed analysis on the progress and prospects for each nation reviewed.

G.史蒂文.生物技术2007:生命科学——一场全球性变革[M]

In BIOTECH 2007 – Life Sciences: A Global Transformation you will find:

·         Special features on emerging players such as China, India, Japan, Singapore and Europe

·         Interviews with biotech leaders

·         2006 Industry Financials, including 12 months of company financial data and market caps for the US, Europe, Canada and Asia

·         An analysis of key activities taking place in various industry sectors including: healthcare, diagnostics, preventative medicine, agbio and industrial biotechnology

·         Industry highlights including: new product approvals, advances in technology, scientific activity, as well as a thorough analysis of the venture capital environment and capital markets

·         600 pages of analysis, data and graphs